Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multicenter, Single-Arm, Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

Next Previous
Search
Trial Profile

An Open Label, Multicenter, Single-Arm, Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 12 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alectinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Expanded access
  • Sponsors Genentech

    • Most Recent Events

    • 24 Oct 2023 Results assessing baseline body mass index (BMI) associated with body weight gain from individual data of patients from J-ALEX, ALUR, ML29453 studies, presented at the 48th European Society for Medical Oncology Congress.
    • 25 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 01 Feb 2016 Planned End Date changed from 1 Apr 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top